Veru (VERU) Interest Expenses (2011 - 2026)
Veru (VERU) posted quarterly Interest Expenses of $228000.0 for Q3 2025, up 15.33% year-over-year from $197693.0 in Q3 2024, and up 67.08% quarter-over-quarter from $136465.0 in Q2 2025.
Veru (VERU) Interest Expenses (2011 - 2026) Analysis & Trends
Veru (VERU) has reported Interest Expenses for 15 consecutive years, with $228000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Interest Expenses rose 15.33% year-over-year to $228000.0; the TTM figure through Dec 2025 stood at $758519.0 (down 5.56% YoY), while the FY2025 annual figure was $831579.0, down 98.85% from the prior year.
- Interest Expenses improved to $228000.0 in Q3 2025 per VERU's latest filing, from $136465.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $98.1 million in Q2 2022 and bottomed at -$1.5 million in Q3 2022.
- Historically, Interest Expenses has averaged $25.4 million across 5 years, with a median of $332826.0 in 2024.
- Annual changes were most pronounced in 2021 — Interest Expenses soared 547.87% — and 2022, when it plunged 226.14%.
- Veru's Interest Expenses stood at $22.7 million in 2021, then surged by 140.98% to $54.6 million in 2022, then plunged by 99.65% to $193104.0 in 2023, then surged by 72.36% to $332826.0 in 2024, then slumped by 31.5% to $228000.0 in 2025.
- Business Quant data shows VERU's Interest Expenses at $228000.0 in Q3 2025, $136465.0 in Q2 2025, and $585.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.29 Mn |
| Jun 30, 2026 | 2.29 Mn |
| Dec 31, 2025 | 194,000.00 |
| Dec 31, 2025 | 194,000.00 |
| Sep 30, 2025 | 228,000.00 |
| Sep 30, 2025 | 228,000.00 |
| Jun 30, 2025 | 136,465.00 |
| Jun 30, 2025 | 136,465.00 |
| Mar 31, 2025 | 585.00 |
| Mar 31, 2025 | 585.00 |
| Dec 31, 2024 | 332,826.00 |
| Dec 31, 2024 | 332,826.00 |
| Sep 30, 2024 | 197,693.00 |
| Sep 30, 2024 | 197,693.00 |
| Jun 30, 2024 | 127,336.00 |
| Jun 30, 2024 | 127,336.00 |
| Mar 31, 2024 | 145,310.00 |
| Mar 31, 2024 | 145,310.00 |
| Dec 31, 2023 | 193,104.00 |
| Dec 31, 2023 | 193,104.00 |